Teva Pharmaceutical Industries (TEVA) Depreciation & Amortization (CF) (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has 18 years of Depreciation & Amortization (CF) data on file, last reported at $241.0 million in Q2 2026.

• Quarterly Depreciation & Amortization (CF) fell 3.98% year-over-year to $241.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $989.0 million (down 3.32% YoY) and the FY2025 annual result came in at $1.0 billion, down 5.38% from the prior year.
• Depreciation & Amortization (CF) grew to $241.0 million in Q2 2026, from $239.0 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $358.0 million in Q2 2022 to a low of $239.0 million in Q1 2026.
• A 5-year average of $278.0 million and a median of $267.5 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) increased 17.38% — and 2023, when it decreased 16.2%.
• Tracing TEVA's Depreciation & Amortization (CF) over 5 years: stood at $306.0 million in 2022, then retreated by 13.07% to $266.0 million in 2023, then rose by 1.13% to $269.0 million in 2024, then decreased by 3.35% to $260.0 million in 2025, then slipped by 7.31% to $241.0 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $241.0 million (Q2 2026), $239.0 million (Q1 2026), and $260.0 million (Q4 2025), per Business Quant data.